500 related articles for article (PubMed ID: 29456411)
21. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir.
Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizábal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
J Viral Hepat; 2014 Aug; 21(8):590-6. PubMed ID: 24188363
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
[TBL] [Abstract][Full Text] [Related]
23. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
[TBL] [Abstract][Full Text] [Related]
24. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
[TBL] [Abstract][Full Text] [Related]
25. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
26. Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy.
Zhang XX; Li MR; Xi HL; Cao Y; Zhang RW; Zhang Y; Xu XY
Chin Med J (Engl); 2016 Apr; 129(8):929-35. PubMed ID: 27064037
[TBL] [Abstract][Full Text] [Related]
27. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
28. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
[TBL] [Abstract][Full Text] [Related]
29. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely.
Cho JY; Sohn W; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park CG
J Viral Hepat; 2020 Sep; 27(9):951-954. PubMed ID: 32338803
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
31. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
32. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
[TBL] [Abstract][Full Text] [Related]
33. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
34. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
[TBL] [Abstract][Full Text] [Related]
36. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
37. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy.
Chen CH; Hu TH; Wang JH; Lai HC; Hung CH; Lu SN; Peng CY
Hepatol Int; 2020 May; 14(3):317-325. PubMed ID: 31650509
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007
[TBL] [Abstract][Full Text] [Related]
39. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
40. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
